Zevra Therapeutics Inc (NASDAQ:ZVRA) price on Friday, April 11, rose 5.18% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $6.90.
A look at the stock’s price movement, the close in the last trading session was $6.56, moving within a range at $6.52 and $6.95. The beta value (5-Year monthly) was 1.94. Turning to its 52-week performance, $9.76 and $4.20 were the 52-week high and 52-week low respectively. Overall, ZVRA moved -13.10% over the past month.
Zevra Therapeutics Inc’s market cap currently stands at around $373.40 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-10.
Analysts have a consensus estimate of 16.96M for the company’s revenue for the quarter, with a low and high estimate of 14.4M and 20.8M respectively. The average forecast suggests up to a 395.13% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 85.06M, representing a 260.23% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that ZVRA is a 100% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
7 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 7 recommend ZVRA as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
ZVRA’s current price about -8.73% and -10.51% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 40.28, while 7-day volatility ratio is 10.09% and 5.79% in the 30-day chart. Further, Zevra Therapeutics Inc (ZVRA) has a beta value of 1.88, and an average true range (ATR) of 0.47. Analysts have given the company’s stock an average 52-week price target of $20, forecast between a low of $18 and high of $22. Looking at the price targets, the low is -160.87% off current price level while to achieve the yearly target high, price needs to move -218.84%. Nonetheless, investors will most likely welcome a -189.86% jump to $20 which is the analysts’ median price.
If we refocus on Zevra Therapeutics Inc (NASDAQ:ZVRA), historical trading data shows that trading volumes averaged 0.57 over the past 10 days and 445.39K over the past 3 months. The company’s latest data on shares outstanding shows there are 53.67 million shares.
The 1.08% of Zevra Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 62.91% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 5.57 million on 2025-03-14, giving us a short ratio of 12.47. The data shows that as of 2025-03-14 short interest in Zevra Therapeutics Inc (ZVRA) stood at 1033.0 of shares outstanding, with shares short falling to 5.78 million registered in 2025-02-14. Current price change has pushed the stock -17.27% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ZVRA stock continues to rise going into the next quarter.
